Your browser doesn't support javascript.
loading
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.
Cremolini, Chiara; Benelli, Matteo; Fontana, Elisa; Pagani, Filippo; Rossini, Daniele; Fucà, Giovanni; Busico, Adele; Conca, Elena; Di Donato, Samantha; Loupakis, Fotios; Schirripa, Marta; Lonardi, Sara; Borelli, Beatrice; Ongaro, Elena; Eason, Katherine; Morano, Federica; Casagrande, Mariaelena; Fassan, Matteo; Sadanandam, Anguraj; de Braud, Filippo; Falcone, Alfredo; Pietrantonio, Filippo.
Afiliação
  • Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Benelli M; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Fontana E; Bioinformatics Unit, Oncology Department, Hospital of Prato, Prato, Italy.
  • Pagani F; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Rossini D; Centre for Molecular Pathology, Royal Marsden NHS Foundation Trust, London, UK.
  • Fucà G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Busico A; Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Conca E; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Di Donato S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Loupakis F; Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Schirripa M; Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Lonardi S; Medical Oncology Unit, Oncology Department, Hospital of Prato, Prato, Italy.
  • Borelli B; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, IRCCS Istituto Oncologico Veneto, Padova, Italy.
  • Ongaro E; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, IRCCS Istituto Oncologico Veneto, Padova, Italy.
  • Eason K; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, IRCCS Istituto Oncologico Veneto, Padova, Italy.
  • Morano F; Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Casagrande M; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Fassan M; Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Sadanandam A; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • de Braud F; Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
  • Falcone A; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
ESMO Open ; 4(2): e000489, 2019.
Article em En | MEDLINE | ID: mdl-30962964
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: ESMO Open Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: ESMO Open Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália